us en false false Default
Skip directly to Accessibility Notice
PPH VanEck Pharmaceutical ETF Please read important disclosure Close important disclosure false

PPH
VanEck Pharmaceutical ETF

PPH
VanEck Pharmaceutical ETF

  • NAV
    $88.27

    as of July 11, 2025
  • YTD RETURNS
    3.61%

    as of July 11, 2025
  • Total Net Assets
    $537.40M

    as of July 11, 2025
  • Total Expense Ratio
    0.36%
  • Inception Date
    12/20/2011

About PPH

VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.

Overview

Why PPH

  • Highly Liquid Companies: Index seeks to track the most liquid companies in the industry based on market capitalization and trading volume
  • Industry Leaders: Index methodology favors the largest companies in the industry
  • Global Scope: Portfolio may include both domestic and U.S. listed foreign companies, allowing for enhanced industry representation

Performance

Fees

Holdings

Portfolio

Sector Weightings (%) as at 06/30/2025

  • Sector

    % of Net Assets
  • Health Care

    99.56
  • Other/Cash

    0.44

Country Weightings (%) as at 06/30/2025

  • Country

    % of Net Assets
  • United States

    62.99
  • United Kingdom

    12.32
  • Switzerland

    7.62
  • Denmark

    7.56
  • France

    4.50
  • Japan

    2.98
  • Israel

    1.59
  • Other/Cash

    0.44

Distributions

Team

Literature

PPH